Approved For Marketing EXPANDED_ACCESS NCT04247906

Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab

Single Patient Expanded Access Treatment Plan (EAP; Also Known As A Compassionate Use Plan) To Provide Patients Access To The Investigational Product Narsoplimab

Sponsor: Impatients N.V. trading as myTomorrows

Conditions Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)

Interventions Narsoplimab

Updated 6 times since 2020 Last updated: Mar 3, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04247906, this observational or N/A phase trial focuses on Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA) and remains ongoing. Sponsored by Impatients N.V. trading as myTomorrows, it has been updated 6 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Mar 2026 — Present [monthly]

Approved For Marketing

Status: Available → Approved For Marketing
Jan 2026 — Mar 2026 [monthly]

Available
Sep 2024 — Jan 2026 [monthly]

Available
Jul 2024 — Sep 2024 [monthly]

Available
Jan 2021 — Jul 2024 [monthly]

Available

▶ Show 1 earlier version

Feb 2020 — Jan 2021 [monthly]

Available

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Impatients N.V. trading as myTomorrows
Omeros Corporation

Data source: Omeros Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.